相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Silent COVID-19: what your skin can reveal
Claudio Guarneri et al.
LANCET INFECTIOUS DISEASES (2021)
Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis
Xintong Li et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE)
R. B. Warren et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis
Ahmed A. Suleiman et al.
CLINICAL PHARMACOKINETICS (2020)
Outcome of cutaneous psoriasis in hepatitis C virus-infected patients treated with Direct-Acting Antiviral therapy
Irene Cacciola et al.
JOURNAL OF VIRAL HEPATITIS (2020)
Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic
Tiago Torres et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2020)
Biological treatment use amid the COVID-19 era, a close look at the unresolved perplexity
Mohammed Shanshal
JOURNAL OF DERMATOLOGICAL TREATMENT (2020)
Should biologics for psoriasis be interrupted in the era of COVID-19?
Mark Lebwohl et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Diversity of clinical appearance of cutaneous manifestations in the course of COVID-19
C. Guarneri et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?
Andrew I. Ritchie et al.
LANCET (2020)
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta et al.
LANCET (2020)
Use of systemic immunomodulatory therapies during the coronavirus disease 2019 (COVID-19) pandemic
Payal Shah et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy
M. Talamonti et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Emilie Sbidian et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2020)
Biologics for the primary care physician: Review and treatment of psoriasis
Eric D. Schadler et al.
DM DISEASE-A-MONTH (2019)
Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials
R. G. Langley et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
Colitis-Induced Th17 Cells Increase the Risk for Severe Subsequent Clostridium difficile Infection
Mahmoud M. Saleh et al.
CELL HOST & MICROBE (2019)
Psoriasis and Inflammatory Bowel Disease
Mario Cottone et al.
DIGESTIVE DISEASES (2019)
Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study
Matteo Megna et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Safety of selective IL-23p19 inhibitors for the treatment of psoriasis
J. J. Crowley et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
Evaluation of a risk score to predict future Clostridium difficile disease using UK primary care and hospital data in Clinical Practice Research Datalink
Clare Marley et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study
Sophie Glatt et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Adalimumab in severe plaque psoriasis of childhood: A multi-center, retrospective real-life study up to 52 weeks observation
Vito D. Lernia et al.
DERMATOLOGIC THERAPY (2019)
Secukinumab for psoriasis in a patient with familial Mediterranean fever
Serafinella P. Cannavo et al.
DERMATOLOGIC THERAPY (2019)
Cardiovascular Risk in Psoriasis: Current State of the Art
Giuseppe Dattilo et al.
CURRENT VASCULAR PHARMACOLOGY (2019)
HIV-associated psoriasis: Epidemiology, pathogenesis, and management
Manuela Ceccarelli et al.
DERMATOLOGIC THERAPY (2019)
Trends in Incidence and Outcomes of Clostridium difficile Colitis in Hospitalized Patients of Febrile Neutropenia A Nationwide Analysis
Nauman S. Siddiqui et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2019)
The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies
Chen-Yu Wu et al.
PLOS ONE (2019)
Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
Simone Ribero et al.
CASE REPORTS IN DERMATOLOGY (2019)
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
A. Deodhar et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics
Christopher T. Ritchlin et al.
BMC RHEUMATOLOGY (2019)
Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study
Vito Di Lernia et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
IL-17 in the lung: the good, the bad, and the ugly
Stephen J. Gurczynski et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2018)
Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects
Sauzanne Khalilieh et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2018)
Risk of Serious Infection, Opportunistic Infection, and Herpes Zoster among Patients with Psoriasis in the United Kingdom
Junko Takeshita et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
Atul Deodhar et al.
LANCET (2018)
Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis
Jason E. Hawkes et al.
JOURNAL OF IMMUNOLOGY (2018)
Psoriasis and Cardiovascular Risk: Correlation Between Psoriasis and Cardiovascular Functional Indices
Giuseppe Dattilo et al.
ANGIOLOGY (2018)
Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
Alvaro Machado et al.
PSORIASIS-TARGETS AND THERAPY (2018)
Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials
Mio Nakamura et al.
DERMATOLOGY AND THERAPY (2017)
Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab
Tiago Torres
DRUGS (2017)
Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management
D. M. Saunte et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Cutaneous and visceral leishmaniasis during anti-TNFα therapy
Claudio Guarneri et al.
WIENER MEDIZINISCHE WOCHENSCHRIFT (2017)
Medical Management of Severe Alcoholic Hepatitis: Expert Review from the Clinical Practice Updates Committee of the AGA Institute
Mack C. Mitchell et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
The microbiota and immune response during Clostridium difficile infection
Erica L. Buonomo et al.
ANAEROBE (2016)
Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases
George E. Fragoulis et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
The Incidence and Predictors of Infection in Psoriasis and Psoriatic Arthritis: Results from Longitudinal Observational Cohorts
Amir Haddad et al.
JOURNAL OF RHEUMATOLOGY (2016)
Serious infections in hospitalized patients with psoriasis in the United States
Derek Y. Hsu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Klebsiella pneumoniae: Going on the Offense with a Strong Defense
Michelle K. Paczosa et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2016)
Analysis of Th17 and Tc17 Frequencies and Antiviral Defenses in Gut-Associated Lymphoid Tissue of Chronic HIV-1 Positive Patients
Gabriella d'Ettorre et al.
MEDIATORS OF INFLAMMATION (2015)
Behavioral and Socioeconomic Risk Factors Associated with Probable Resistance to Ceftriaxone and Resistance to Penicillin and Tetracycline in Neisseria gonorrhoeae in Shanghai
Molly A. Trecker et al.
PLOS ONE (2014)
Clostridium difficile: A European perspective
A. M. Jones et al.
JOURNAL OF INFECTION (2013)
分享论文
